Gene-editing company Inscripta, formerly known as Muse Biotechnologies, will be able to expand its research capabilities and increase hiring after the company closed a Series C funding round of $55.5…

Today, on this 11th World Rare Disease Day, life science companies, organization and activists have come together to raise awareness about these diseases and the needs of therapies for patients.…

Reata Pharmaceuticals has updated the timing of coming data announcements for two ongoing mid-stage trials for rare renal diseases. Source: BioSpace

PharmaCyte Biotech recently discussed its options and plans for a Phase IIb clinical trial of its Cell-in-a-Box technology in pancreatic cancer. Source: BioSpace

Galera Therapeutics has initiated its Phase I/II clinical trial of GC4419 in locally advanced pancreatic cancer (LAPC). Source: BioSpace

After a huge dry spell in M&A, 2018 is shaping up to be a great year for deal making. Source: BioSpace

Cambridge, Massachusetts-based Generation Bio closed on a $100 million Series B financing today. Source: BioSpace

Senti Biosciences, based in South San Francisco, has completed a $53 million Series A financing. Source: BioSpace

Eli Lilly snagged regulatory approval for expanded use of cancer treatment Verzenio. Source: BioSpace

David Lucchino, chief executive officer of Frequency Therapeutics, is expected to be named the next chairman of MassBio next month. Source: BioSpace